April 7, 2005
NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating MelanomaTopics: Medical Science News
The results of a study at the NCI indicate that a combination of chemotherapy and infusion of stimulated autologous lymphocytes can have an impact on metastatic melanoma tumors in patients who do not respond to other therapies.
(...) A team of researchers, led by Steven A. Rosenberg, M.D., at the National Cancer Institute, part of the National Institutes of Health, have found that patients with advanced melanoma who had not responded to previous therapies experienced a significant reduction in the size of their cancers as a result of receiving a new immunotherapy. This immunotherapy consisted of a combination of chemotherapy and reintroduction of their own (autologous) activated lymphocytes. Autologous lymphocytes are white blood cells that have been removed from the patient, activated or re-educated to attack the tumor, then reintroduced into the patient. The promise of this therapy is that a patient's own immune system can be used to effectively treat existing tumors. Results are reported in the April 2005 issue of the Journal of Clinical Oncology.*
1. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
2. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
3. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Posted by Richard at April 7, 2005 9:51 AM
Articles Related to Medical Science News: